Spartak Zekja

No defence statement reported in the sources reviewed.

Sorted by reported money, then by linked people and their legal status. The money figure is the largest single reported figure, not a total.

A case listed here names this person. It does not mean they are accused in it; read the case page.

Possible explanations that connect this record with other findings. They are not findings; each lists the evidence for and against.

• Source label: Unverified

  FSDKSH controls failed in several ways at once: fictitious reimbursement, unperformed check-ups and unpunished oncology delays

  The depot case alleges fictitious inventories billed to FSDKSH (Nov 2025). Vetting (Mar 2026) reports a Check-Up concession paying a fixed fee for about 475,000 checks while about 467,000 were performed in 2023, 49 documented cancer-drug delays since 2020 with about 49 million lekë penalties never collected, and ten directors in ten years. The common thread is weak verification before payment.

  Evidence for

  • Prosecution alleges fictitious inventories and invoices claimed as reimbursement, and that three fund employees did not physically check medicines (Shqiptarja, 2025).
  • Vetting reports the fixed-fee Check-Up payment regardless of volume and weak contract monitoring (Vetting, 2026).
  • Vetting reports 49 cancer-drug delays and penalties not collected.

  Evidence against

  • The depot case is an allegation under prosecution review; no verdict exists.
  • The Check-Up and oncology problems are documented by Vetting and by an earlier KLSH finding, but no SPAK charge on them was found; these are separate matters that may not share a cause.
  • Turnover of directors may reflect political change, not a single control failure.

• Official position→Compulsory Health Care Insurance Fund (FSDKSH)Source label: Officially reported

  Former director of FSDKSH

  Evidence: Shqiptarja (2025-11-04) identifies him as former FSDKSH director; Vetting (2026-03-05) lists him among 10 directors 2015-2025.